Payment overview · 2025
General Payments
$22,587.97
199 reported records · 27 companies
Healthcare provider profile · identity verified
William Lee Smits, M.D.
Allopathic & Osteopathic Physicians|Allergy & Immunology · FORT WAYNE, IN · NPI 1811950462
Verified facts
What the public records show
CMS Open Payments records show William Lee Smits, M.D. received $22,587.97 in general payments during 2025 across 199 reported records.
AstraZeneca Pharmaceuticals LP accounted for 86.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hizentra, Nucala, Nurtec Odt, Tezspire, Trelegy Ellipta, Xolair.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tezspire by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Hizentra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 387 claims for Trelegy Ellipta by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gamunex-C by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xolair by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Cuvitru by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19,510.22 | 86.4% | 44 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $482.35 | 2.1% | 32 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $458.65 | 2.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $295.54 | 1.3% | 26 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $275.26 | 1.2% | 15 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $222.15 | 1.0% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $181.16 | 0.8% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $149.08 | 0.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $134.20 | 0.6% | 6 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $129.30 | 0.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $106.15 | 0.5% | 5 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $90.64 | 0.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.80 | 0.3% | 4 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $72.42 | 0.3% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.48 | 0.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $59.38 | 0.3% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.90 | 0.2% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $41.34 | 0.2% | 2 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $39.93 | 0.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.17 | 0.1% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $27.19 | 0.1% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $21.30 | 0.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $18.83 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.25 | 0.1% | 1 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $15.99 | 0.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.57 | 0.1% | 2 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $3.72 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,150.00 | 12 |
| Food and Beverage | $4,048.74 | 180 |
| Travel and Lodging | $321.86 | 4 |
| Education | $51.38 | 2 |
| Consulting Fee | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $11,780.71 | 17 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $7,634.77 | 17 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $580.71 | 20 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $297.70 | 20 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $283.79 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $272.79 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $248.67 | 23 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $230.09 | 10 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $222.15 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $194.54 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.37 | 11 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION, SANOFI US SERVICES INC. | $156.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $134.87 | 9 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $127.47 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $90.64 | 5 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $68.48 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $64.45 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $59.38 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $48.90 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | HOSPIRA, INC., PFIZER INC. | $36.62 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., PFIZER INC. | $34.81 | 5 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $28.17 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC., PFIZER INC. | $20.01 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ALTERNARIA TENUIS Normalized: alternaria tenuis |
Biological | ALK-Abello, Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| PRE-PEN Normalized: pre pen |
Drug | ALK-Abello, Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| STANDARDIZED MITE D. FARINAE Normalized: standardized mite d farinae |
Biological | ALK-Abello, Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| TIMOTHY, STANDARDIZED Normalized: timothy standardized |
Biological | ALK-Abello, Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.57 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.28 | 1 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $12.27 | 1 | 2025 |
Source payment records
|
|||||
| EUCRISA Normalized: eucrisa |
Drug | PFIZER INC. | $12.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Hizentra hizentra |
2025 | Hizentra | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 387 | exact normalized | Medicare Part D |
| XOLAIR xolair |
2025 | Xolair | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
271 | 84 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
387 | 98 |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 920 | 261 |
| Famotidine | Famotidine | 856 | 286 |
| Azithromycin | Azithromycin | 799 | 254 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 635 | 320 |
| Omeprazole | Omeprazole | 440 | 131 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 387 | 98 |
| Fluticasone Propionate | Fluticasone Propionate | 285 | 120 |
| Prednisone | Prednisone | 272 | 124 |
| Symbicort | Budesonide/Formoterol Fumarate | 271 | 84 |
| Azelastine Hcl | Azelastine Hcl | 260 | 117 |
| Albuterol Sulfate | Albuterol Sulfate | 204 | 73 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 193 | 66 |
| Breo Ellipta | Fluticasone/Vilanterol | 192 | 42 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 169 | 50 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 162 | 43 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 159 | 60 |
| Amitriptyline Hcl | Amitriptyline Hcl | 136 | 38 |
| Rizatriptan | Rizatriptan Benzoate | 135 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 27 |
| Promethazine Hcl | Promethazine Hcl | 113 | 25 |
| Arnuity Ellipta | Fluticasone Furoate | 110 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 44 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 101 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 35 |
| Meclizine Hcl | Meclizine Hcl | 101 | 40 |
| Methylprednisolone | Methylprednisolone | 89 | 47 |
| Theophylline Er | Theophylline Anhydrous | 76 | 20 |
| Fluconazole | Fluconazole | 68 | 45 |
| Spiriva Respimat | Tiotropium Bromide | 67 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 65 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 64 | 27 |
| Dulera | Mometasone/Formoterol | 62 | 16 |
| Hydrocortisone | Hydrocortisone | 62 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 21 |
| Spironolactone | Spironolactone | 62 | 14 |
| Sucralfate | Sucralfate | 58 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 57 | 34 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 54 | 18 |
| Epinephrine | Epinephrine | 53 | 36 |
| Dupixent Syringe | Dupilumab | 52 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 30 |
| Fasenra Pen | Benralizumab | 49 | suppressed |
| Furosemide | Furosemide | 49 | 18 |
| Topiramate | Topiramate | 48 | 13 |
| Qvar Redihaler | Beclomethasone Dipropionate | 47 | 21 |
| Dupixent Pen | Dupilumab | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 14 |
| Xolair | Omalizumab | 42 | suppressed |
| Clarithromycin | Clarithromycin | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 23 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 37 | suppressed |
| Roflumilast | Roflumilast | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Cefdinir | Cefdinir | 36 | 28 |
| Zafirlukast | Zafirlukast | 36 | 16 |
| Cefuroxime | Cefuroxime Axetil | 35 | 18 |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 34 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Alvesco | Ciclesonide | 31 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 31 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Nucala | Mepolizumab | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 24 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 18 |
| Desloratadine | Desloratadine | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Tezspire | Tezepelumab-Ekko | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Itraconazole | Itraconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Omnaris | Ciclesonide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,587.97 · 199 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, ALTERNARIA TENUIS, AREXVY, AYVAKIT, Arikayce, BREZTRI, Brinsupri, CIBINQO, CUTAQUIG, DUPIXENT, EBGLYSS, EUCRISA, FASENRA, GLASSIA, Hizentra, NEFFY, NEMLUVIO, NUCALA, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORLADEYO, PANZYGA, PRE-PEN, Prolastin-C Liquid, QULIPTA, RINVOQ, RUCONEST, Rhapsido, SHINGRIX, SMARTVEST, STANDARDIZED MITE D. FARINAE, Symbravo, TEZSPIRE, TIMOTHY, STANDARDIZED, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XOLAIR, Xembify, Xhance, YUPELRI, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hizentra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error